http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023014870-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2be1effe2aad8610d58162b6e1f93fb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-056 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-056 |
| filingDate | 2020-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10f26eb5bac891118df20244ff042779 |
| publicationDate | 2023-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2023014870-A1 |
| titleOfInvention | Novel galactoside inhibitor of galectins |
| abstract | The present invention relates to a D-galactopyranose compound of formula (1) n n n n n n n n n n whereinn nthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021380624-A1 |
| priorityDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 723.